United Kingdom Pharmaceuticals & Healthcare Report Q4 2013 - New Market Research Report
Keen to consolidate public spending, and despite the clear success of the Pharmaceutical Price Regulation Scheme (PPRS), the government has identified drug prices as an area to focus on. In addition to restructuring the statutory PPRS, including a 10%, 15% or 20% downward price adjustment to drugs sold under the existing statutory scheme (which covers approximately 10% of the branded medicines consumed in the UK), the UK government is also aiming to implement a new value-based medicine pricing system that...
View full press release